Sclerosis, Multiple
Conditions
Keywords
Sleep assessment, Neuromuscular Fatigability, Multiple sclerosis, Chronic fatigue
Brief summary
Chronic fatigue is the most common and debilitating symptom in multiple sclerosis patients. This chronic fatigue affects their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in this feeling of chronic fatigue. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology will allow to optimize rehabilitation treatments to decrease the apparition/persistence of chronic fatigue and in fine improve quality of life.
Interventions
OTHEREvaluation of degree chronic fatigue.
Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
OTHERQuestionnaires
* Fatigue Severity Scale (FSS) * Modified Fatigue Impact Scale (MFIS) * Godin Leisure-Time Exercise Questionnaire (GLTEQ) * Scale of life quality of multiple sclerosis (SEP-59) * Center for Epidemiologic Studies Depression (CES-D) * Pittsburgh Sleep Quality Index (PSQ-I)
BIOLOGICALBlood sample
Blood sample will be realized to evaluate anemia and inflammations.
OTHERCardiopulmonary evaluation
Cardiopulmonary evaluation will be realized with a cycle ergometer.
DEVICECapacity of muscular oxygen extraction
Measure the capacity of muscular oxygen extraction with a cycle ergometer.
DEVICESleep assessment
Sleep assessment will be measured by actigraphy during 15 days.
DEVICEMetabolic fatigue
Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
Neuromuscular evaluation will be measured by the composite of the results of: * Fatigue test * Measure of voluntary isometric force * Surface electromyography * Peripheral nerve stimulation * Transcranial Magnetic Stimulation (TMS) * Perceived fatigue * Cognitive fatigue * Thermoregulation
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
For Patients: * Aged ≥ 18 and ≤ 70 years * Men or women * With multiple sclerosis since 2 and 25 years * Affiliates or beneficiaries of social security scheme * Signed consent For Healthy volunteers: * Aged ≥ 18 and ≤ 70 years * Men or women * Matched in accordance with age, sex and level of physical activity
Exclusion criteria
For Patients and Healthy volunteers: * High heart rate resting * Blood pressure \> 144/94 mmHg * Recent adjustment of drug or drug can have an impact on fatigue or stimulant for fatigue * Taking neuroactive substances that can alter corticospinal excitability * Contraindication at application magnetic field * Contraindication at Magnetic Resonance Imaging (MRI) * Currently participating in a structured exercise program * Pregnant For Patients only: * Spasticity or cerebellar ataxia * Abnormal range of motion (toe and/or ankle) * Musculoskeletal injuries that impedes pedaling * Appearance of symptoms of multiple sclerosis in the 90 days preceding the study For Healthy volunteers: \- Neurological diseases, cardiovascular, musculoskeletal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Voluntary maximum contraction | Day : 30 | Comparison the percentage of decrease in voluntary maximum contraction reported after the fatiguing task. Measured by an instrumented measuring pedal (PowerForce pedal, Model PF1.0.0.0, Radlabor GmbH, Freiburg, Germany) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle oxygen extraction capacity | Day : 30 | Measured by near-infrared spectroscopy (NIRS) |
| Anemia | Day : 30 | Measured by blood count in blood sample |
| Inflammation | Day : 30 | Measured by C-reactiv protein in blood sample |
| VO2 max | Day : 30 | Measured by effort test |
| Heart rate | Day : 30 | Measured by heart rate monitor |
| Neuromuscular function during the dynamic strenuous exercise | Day : 30 | Cortical activity by transcranial magnetic stimulation, evaluated by recording of the evoked motor potentials . |
| Perceived fatigue | Day : 30 | Measured by Borg scale |
| Thermoregulation | Day : 30 | Measured by digestible thermometric pill (e-celcius Performance) |
| Sleep quality | Day : 30 | Measured by actigraphy |
| Muscle volume | Day : 30 | Measured by Magnetic Resonance Imaging |
| Metabolic fatigue | Day : 30 | Measured by a Phosphorus 31 Nuclear Magnetic Resonance test |
| Cognitive fatigue | Day : 30 | Measured by Symbol Digit Modalities Test |
Countries
France
Outcome results
None listed